<?xml version="1.0" encoding="UTF-8"?>
<p>Ezetimibe is a novel drug for the treatment of dyslipidemia, which selectively inhibits cholesterol absorption by inhibiting Niemannâ€“Pick C1-like protein (NPC1L1). Ezetimibe reduced the postprandial TG-AUC and apoB100 concentration and reduce postprandial endothelial dysfunction (
 <xref rid="B120" ref-type="bibr">120</xref>). In type IIB hyperlipidemia patients, ezetimibe significantly reduced fasting TG, LDL-C, apoB48, and apoB100 levels as well as postprandial TG and apoB48 (
 <xref rid="B121" ref-type="bibr">121</xref>). It is reported that ezetimibe can improve TG and endothelial function in patients with CHD and hypertriglyceridemia during statin treatment (
 <xref rid="B122" ref-type="bibr">122</xref>). Ezetimibe combined with statins reduced the secretion of apoB48, which may be achieved by affecting the metabolism of TRL in intestinal cells (
 <xref rid="B123" ref-type="bibr">123</xref>). In addition, ezetimibe combined with statins reduced the incidence of long-term cardiovascular end events in patients with acute coronary syndrome (
 <xref rid="B124" ref-type="bibr">124</xref>). Therefore, the study of statins combined with ezetimibe to improve postprandial blood lipid levels is worthy of attention.
</p>
